A groundbreaking drug for pancreatic cancer is now showing promise against the most common form of lung cancer. In a small trial, the drug shrank tumors in 31 to 37 percent of patients, depending on the dose. The next step is a larger trial. A groundbreaking drug for pancreatic cancer is now showing promise against the most common form of lung cancer. In a small trial, the drug shrank tumors in 31 to 37 percent of patients, depending on the dose. The next step is a larger trial.
Pancreatic Cancer Drug Shows Promise in Lung Cancer TrialPancreatic Cancer Drug Shows Promise in Lung Cancer Trial
